Very small pancreatic cystic tumors: observe or treat?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Very small pancreatic cystic tumors are safe to observe, rather than treat, in patients with no symptoms and no radiographic features associated with malignancy, according to a study of patients with neoplasms less than 3 cm in size.

WASHINGTON—Very small pancreatic cystic tumors are safe to observe, rather than treat, in patients with no symptoms and no radiographic features associated with malignancy, according to a study of patients with neoplasms less than 3 cm in size.

Recent international consensus guidelines suggest that patients with these small tumors do not need immediate treatment. However, there have been few published data up to now to support that recommendation. The purpose of this study was to determine the rate of malignancy among patients with pancreatic cystic tumors less than 3 cm and the incidence of symptoms and radiographic features suggesting malignancy.

The researchers found that about 3.3% of patients with very small tumors and no symptoms or radiographic features had a malignant tumor. As a result, "we have concluded that the international guidelines are appropriate," commented C. J. Lee, MD, of the University of Michigan Medical School, Ann Arbor, who presented the findings at Digestive Disease Week 2007 (abstract 278).

Led by Diane Simeone, MD, the researchers used databases from five high-volume pancreatic centers to identify 166 resected neoplasms less than 3 cm in size. For each neoplasm, they looked at predictors of malignancy, such as age, sex, and symptoms, including abdominal pain, nausea and vomiting, jaundice, pancreatitis, unexplained weight loss, and anorexia.

The investigators also reviewed radiographic features of concern, including the presence of a mass, lymphadenopathy, or dilated main pancreatic or common bile ducts.

Of the 166 cases identified, 31 were malignant. Men and older patients were more likely to have malignant tumors, Dr. Lee reported.

The great majority of patients with malignancy (96%) had symptoms, including abdominal pain (55%), weight loss (35%), jaundice (32%), and pancreatitis (14%). Most also had at least one radiographic feature of concern.

Of 30 patients with no symptoms, only one had a malignant tumor. "That 3.3% rate of malignancy is the same as the mortality rate from major pancreatic surgery," Dr. Lee said.

The authors concluded that patients who have very small tumors with no other symptoms or radiographic indicators have a very low risk of malignancy and can be managed initially with monitoring rather than surgery.

Recent Videos
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Related Content